Immupharma Share Discussion Threads

[hamhamham1] 07/1/2018 08:29

I wonder if this text from the link I posted means that Mauritius requested for an 'open label extension'?
==Professor Sylviane Muller, to visit the country in May and meet with lawmakers, health policymakers and rheumatologists. The meetings were followed by the request for the trial’s extension.==
An open label extension is described below,
==Do participants still get treatment after the trial ends?
After the trial ends, treatment may end, or participants may be offered continued treatment. This is frequently referred to as an “open label extension.” Participants who have received placebo are sometimes able to get the treatment at the end of a study as well. To understand what happens after the trial ends, it is important to speak with the individuals conducting the trial to see if the option exists to continue the treatment after the trial has ended.==

[vatpaul] 07/1/2018 08:09

The conclusion from bmj in p2b trial

In conclusion, the results of this study showed that Lupuzor provided statistically significant and clinically meaningful improvement of disease activity in a subpopulation of lupus patients with a SLEDAI-2K score ≥6 with a more pronounced effect in a population with a clinical SLEDAI score ≥6.

[wigwammer] 07/1/2018 08:04

"This is a BB - I share with you my views."Your view (which keeps changing) is that a £650m+ company is going to have difficulty raising £3m. So either your view is very daft or your view is intended to mislead and cause mischief. I suspect many of those who gave you the benefit of the doubt are having second thoughts, especially if they have upwards of a single brain cell. Have a great Sunday :)

[hamhamham1] 07/1/2018 07:54

L0ngterm. Yes, Mauritius were very keen to get involved in the ph3 trialing process.
hxxps://lupusnewstoday.com/2016/09/09/immupharma-extends-phase-3-study-of-lupus-therapy-lupuzor-to-mauritius

[flavio_monteiro] 07/1/2018 07:10

If the Phase 3 results are good....IMM could secure debt funding. Motif Bio achieved this in November 2017. This was achieved even before Phase 3 data has been logged with the FDA.

Motif Bio secures up to US$20 million debt financing

London and New York, Motif Bio plc (AIM/NASDAQ: MTFB), a clinical stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has entered into an agreement for up to US$20 million in debt financing with Hercules Capital, Inc. (NYSE: HTGC), a leader in customised debt financing for companies in life sciences and technology-related markets. The funds will be used to fund pre-commercialisation activities and other corporate activities in preparation for the anticipated US launch of iclaprim in 2019.

I own share in both IMM & MTFB.

[immy1992] 07/1/2018 06:53

I for one am just looking forward to tomorrow

[runtoma] 07/1/2018 06:14

spawny 99.5% of us are in agreement with you. The medical rep is not

[spawny100] 07/1/2018 04:33

That's the point I've already made 1retirement but glad you're in agreement!

[l0ngterm] 07/1/2018 03:39

Add to the mix that Mauritius a country with a high number of sufferers. Have A requested that iMM conduct trials there, and B if successfully at phase iii will not be waiting for a deal. Their could be cash generated from sales, to meet this demand sooner than we think.I also do not believe that Mauritius will be waiting for FDA approval either.

[runtoma] 06/1/2018 23:25

Medical Rep njb67 You said it!

[njb67] 06/1/2018 23:15

Posting a lie is desperate.

This is a BB - I share with you my views. You are ultimately responsible for your own decisions.

GLA.

[spawny100] 06/1/2018 23:03

njb67

Desperate.

[markymark33] 06/1/2018 22:59

you have 2 alta egos... the scientist and the M & A specialist

you try far too hard to be credible. Someone in your game wouldn't bother with this board

qaz is spot on with his analysis

[njb67] 06/1/2018 22:53

mm

Desperate.

[markymark33] 06/1/2018 22:52

njb = nobbygnome, posts from the same IP address....

[qazwsxedc69] 06/1/2018 22:45

Njb - whatever you say, I for one find it beyond co-incidence that you admit to knowing nobbygnome and have the same Inability to let a point pass, and same snidey posting style.....

[wigwammer] 06/1/2018 22:42

Njb... So your (latest) point is that if the ph3 result is positive then things will be good, and if the ph3 result is inconclusive then things will be bad. Again - with due respect - this is not very enlightening. Better just to admit the "running out of money" point wasn't a very good one, otherwise people may feel justified in believing you are here to cause mischief.

[njb67] 06/1/2018 22:37

met
so why is it needed if the results are guaranteed to replicate phase 2 studies?

[metis20] 06/1/2018 22:36

Of course a phase 3 study is required!

[njb67] 06/1/2018 22:33

wig

I agree. If results are positive, then they will either do a commercial deal or raise the capital they need until they do a deal. With positive results, the latter will be relatively straight forward.

We were talking about what would happen if the Ph3 results are inconclusive. IMM would need new investment to stay solvent and with question marks over Lup / P140 platform, then that becomes a lot more difficult and damaging to existing shareholders.

metis
I hope for their sake SCSW are correct then. If the results are positive and guaranteed, then why have IMM been asked to do the Ph3 study....

On SCSW, if everyone of their picks was guaranteed to succeed, then why are we not all backing their 100% nailed on winners? In fact, why do we have a whole investment industry investing in anything apart from what SCSW are "napping"? How did last years naps do btw?

[metis20] 06/1/2018 22:18

67.6% responders after 12 weeks and 84.2% responders after 24 weeks

Above from

Does not look as if we have to bother about "what ifs" surrounding a phase 3 failure, especially when phase 2b and phase 3 are so similar in approach

phase 2b - 149 patients enrolled - The patients received 200μg of the P140/Lupuzor peptide or a placebo as a subcutaneous injection once every four weeks for 24 weeks.

phase 3 - 200 patients enrolled - The patients received 200μg of the P140/Lupuzor peptide or a placebo as a subcutaneous injection once every four weeks for 48 weeks.

I also find it of interest that the SCSW note made no reference to risk of failure, even though IMM is one of SCSW's 2018 NAPS. A lot of egg on face for SCSW if one of their 2018 NAPS has a share price which collapses two or three months into the year!

[spawny100] 06/1/2018 22:16

Second that. Look at VAL to see just how easy and luctrative fundraising can be even when you are valued in pocket money. Incidentally VAL is one nobby seems to have high hopes for and is invested in.